Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
Ruxolitinib bij intermediair-1 risico myelofibrose
dec 2017 | MPN, Stamceltransplantatie